- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00878423
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724-5024
- The University of Arizona Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114-2696
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed informed consent.
- Age 18 years or older.
Histological or cytological evidence of a metastatic solid tumor including lymphoma, which is refractory to standard therapy. The following tumor types are of particular interest as they may be more likely to respond to HSP90 inhibition and all efforts should be made to recruit patients into the study with these diagnoses. Only patients with these diagnoses and others thought to be responsive to HSP90 inhibitors are to be enrolled following the identification of MTD.
- Metastatic breast cancer which is HER2 positive either by FISH or 3+ immunohistochemistry staining,
- Adenocarcinoma of the prostate which is refractory to treatment with androgen depletion,
- Metastatic melanoma,
- Stage IIIb or IV NSCLC,
- SCLC,
- High grade gliomas (patients must have been on a stable dose of corticosteroids for at least one week prior to treatment with AT13387 and have not experienced neurological deterioration during this period),
- GIST.
- ECOG performance status ≤ 2.
Adequate marrow function as defined by:
- Hemoglobin > 9 g/dL,
- Neutrophils > 1.4 x 10^9/L,
- Platelets ≥ 100 x 10^9/L.
- Negative serum or urine pregnancy test or evidence of surgical sterility or evidence of post-menopausal status. Post-menopausal status is defined as any of the following: natural menopause with menses >1 year ago; radiation induced oophorectomy with last menses >1 year ago; chemotherapy-induced menopause with 1 year interval since last menses.
Exclusion Criteria:
- Be pregnant or lactating (women of childbearing potential must have a negative pregnancy test within 7 days prior to enrolment). Male and female patients of childbearing potential must use appropriate birth control (barrier methods, oral contraceptives and/or intrauterine devices) during the entire duration of the study, or the patient must be surgically sterile (with documentation in the patient's medical records).
- Ongoing central nervous system metastases in patients with an extracranial primary tumor (unless the patient's neurological signs or symptoms have been stable during the preceding three months and the patient has not received corticosteroid treatment for four weeks prior to study entry).
- Inadequate liver function as demonstrated by serum bilirubin > 2.5 times the upper limits of reference range (ULRR) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or alkaline phosphatase (ALP) ≥ 2.5 times the ULRR (unless due to the presence of liver metastases when ALT and/or AST may be up to five times the upper limits of reference range). Patients with an isolated increase in ALP ≤ 5 times ULRR in the absence of liver metastases but with known bone metastases are eligible for the study.
- Left ventricular ejection fraction <50% on echocardiography or MUGA scan.
- Moderate or severe renal impairment defined as serum creatinine > 1.5 ULRR or > + proteinuria on two occasions no less than 24 hours apart.
- Previous treatment with a HSP90 inhibitor.
- Anticancer therapies that have not been completed at least 28 days prior to treatment with AT13387 (other than surgery or treatment with a protein kinase inhibitor which must have been completed no less than one week prior to treatment with AT13387).
- Incomplete recovery from previous radiotherapy or surgery other than residual cutaneous effects or stable < Grade 2 gastrointestinal toxicity.
- History of an ischemic cardiac event, myocardial infarction or unstable cardiac disease within 3 months of study entry.
- QTc > 460 ms according to the Fridericia's correction.
- Previous malignancy, except for non-basal-cell carcinoma of skin or carcinoma-in-situ of the uterine cervix, unless the tumor was treated with curative intent more than 2 years prior to study entry.
- Any evidence of severe or uncontrolled systemic conditions (e.g., systemic infection) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
- Prior history of infection with human immunodeficiency virus (HIV), known active hepatitis B or C viruses - screening for viral infections is not required for entry to this study.
- Chronic treatment with known CYP450 inducers e.g. phenytoin, within four weeks of receiving treatment with AT13387 (see Appendix D for list) other than Dexamethasone in patients with glioma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The identification of the maximum tolerated dose for twice or once weekly dosing, on three weeks out of four
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic profile, Safety and tolerability of maximum tolerated dose, pharmacodynamic effect, identify dose limiting toxicities
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Geoffrey Shapiro, MD PhD, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT13387/0001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
-
Jiangsu Simcere Pharmaceutical Co., Ltd.UnknownAdvanced Solid Tumors | Metastatic Solid TumorsChina
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
-
University of AlbertaWithdrawnLocally Advanced Solid Tumors | Metastatic Solid TumorsCanada
-
OBI Pharma, IncTerminatedLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States, Taiwan
Clinical Trials on AT13387
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Recurrent...United States
-
National Cancer Institute (NCI)WithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
-
Astex Pharmaceuticals, Inc.CompletedNon-small Cell Lung Cancer(NSCLC)United States, Korea, Republic of, Spain, France, Canada
-
Astex Pharmaceuticals, Inc.CompletedGastrointestinal Stromal Tumor (GIST)United States
-
National Cancer Institute (NCI)CompletedUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid NeoplasmUnited States
-
National Cancer Institute (NCI)TerminatedTriple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Advanced Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Astex Pharmaceuticals, Inc.CompletedProstate CancerUnited States, United Kingdom, Spain, Canada